<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623699</url>
  </required_header>
  <id_info>
    <org_study_id>233AS101</org_study_id>
    <secondary_id>2015-004098-33</secondary_id>
    <nct_id>NCT02623699</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Study of BIIB067 in Adults With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>A Phase 1, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety, tolerability, and
      pharmacokinetics (PK) of BIIB067 in adults with ALS. The secondary objective is to evaluate
      the effects of BIIB067 on levels of superoxide dismutase 1 (SOD1) protein in the
      cerebrospinal fluid (CSF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2016</start_date>
  <completion_date type="Anticipated">February 2, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory assessment abnormalities</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant vital sign abnormalities</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant physical examination abnormalities</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant neurological examination abnormalities</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of BIIB067 in plasma: Maximum observed concentration (Cmax)</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of BIIB067 in plasma: Time to reach maximum observed concentration (Tmax)</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of BIIB067 in plasma: Area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of BIIB067 in plasma: Area under the concentration-time curve from time zero to the time of the last measurable concentration (AUClast)</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of BIIB067 in plasma: Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of BIIB067 in CSF levels: Terminal elimination half-life (t1/2)</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CSF levels of SOD1 protein.</measure>
    <time_frame>up to day 169</time_frame>
    <description>Part A: up to day 57; Part B: up to day 169</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Randomized single ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B: Randomized multiple ascending dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB067</intervention_name>
    <description>Part A and B</description>
    <arm_group_label>Single Ascending Dose</arm_group_label>
    <arm_group_label>Multiple Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Part A and B</description>
    <arm_group_label>Single Ascending Dose</arm_group_label>
    <arm_group_label>Multiple Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Weakness attributable to ALS and documented SOD1 mutation at Screening Visit 2.

          -  A forced vital capacity (FVC) ≥50% of predicted value as adjusted for sex, age, and
             height (from the sitting position). Participants with stable FVC &lt;50% but ≥45%, whose
             FVC has not declined by more than 5% in the last 6 months may be considered for
             inclusion, at the discretion of the Investigator.

          -  If taking riluzole, Participant must be on a stable dose for ≥30 days prior to Day 1
             and expected to remain at that dose until the final study visit.

          -  Medically able to undergo the study procedures, and to adhere to the visit schedule at
             the time of study entry, as determined by the Investigator.

        Key Exclusion Criteria:

          -  History of or positive test result for human immunodeficiency virus.

          -  History of, or positive test result at Screening, for hepatitis C virus antibody.

          -  Current hepatitis B infection (defined as positive for hepatitis B surface antigen
             [HBsAg] and/or hepatitis B core antibody [HBcAb]). Participants with immunity to
             hepatitis B from previous natural infection (defined as negative HBsAg, positive
             hepatitis B surface antibody immunoglobulin G, and positive HBcAb) or vaccination
             (defined as positive anti-HBs) are eligible to participate in the study.

          -  Treatment with another investigational drug, biological agent, or device within 1
             month or 5 half-lives of study agent, whichever is longer. Specifically, no prior
             treatment with small interfering ribonucleic acid, stem cell therapy, or gene therapy
             is allowed.

          -  Current enrollment in any other interventional study.

          -  Current or recent (within 1 month) use, or anticipated need, in the opinion of the
             Investigator, of copper (II) (diacetyl-bis (N4-methylthiosemicarbazone)) or
             pyrimethamine.

          -  Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing
             system (DPS) during the study period.

          -  Tracheostomy

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Biogen</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0949</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital, MA</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group, LLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute Clinical Research Unit</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Norrlands universitetssjukhus</name>
      <address>
        <city>Umea</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheffield Institute for Translational Neuroscience</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Isis-SOD1Rx</keyword>
  <keyword>SOD1</keyword>
  <keyword>ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

